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Abstract
Purpose The aim of the study was to develop a European list
of potentially inappropriate medications (PIM) for older peo-
ple, which can be used for the analysis and comparison of
prescribing patterns across European countries and for clinical
practice.
Methods A preliminary PIM list was developed, based on the
German PRISCUS list of potentially inappropriate medica-
tions and other PIM lists from the USA, Canada and France.
Thirty experts on geriatric prescribing from Estonia, Finland,
France, the Netherlands, Spain and Sweden participated; eight
experts performed a structured expansion of the list, suggest-
ing further medications; twenty-seven experts participated in a
two-round Delphi survey assessing the appropriateness of
drugs and suggesting dose adjustments and therapeutic alter-
natives. Finally, twelve experts completed a brief final survey
to decide upon issues requiring further consensus.
Results Experts reached a consensus that 282 chemical sub-
stances or drug classes from 34 therapeutic groups are PIM for
older people; some PIM are restricted to a certain dose or
duration of use. The PIM list contains suggestions for dose
adjustments and therapeutic alternatives.
Conclusions The European Union (EU)(7)-PIM list is a
screening tool, developed with participation of experts from
seven European countries, that allows identification and com-
parison of PIM prescribing patterns for older people across
European countries. It can also be used as a guide in clinical
practice, although it does not substitute the decision-making
process of individualised prescribing for older people. Further
research is needed to investigate the feasibility and applicabil-
ity and, finally, the clinical benefits of the newly developed
list.
Keywords Potentially inappropriate medication .
Inappropriate prescribing [MeSH term] . Aged [MeSH term] .
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Background
Appropriate prescribing for older people is a public health
concern, and several assessment tools are available for its
evaluation. Most of the tools focus on pharmacological appro-
priateness of prescribing [1]; they address various aspects of
appropriateness, including overprescribing of medications
that are clinically not indicated, omission of medications that
are needed, and incorrect prescriptions of medications that
may be indicated [2]. The term Bpotentially inappropriate
medications (PIM) for older people^ has been used to refer
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to those drugs which should not be prescribed for this popu-
lation because the risk of adverse events outweighs the clinical
benefit, particularly when there is evidence in favour of a
safer or more effective alternative therapy for the same con-
dition [3, 4].
The prevalence of inappropriate prescribing and/or use of
PIM has been analysed by several authors and ranges from 20
to 79 % depending on the population studied, the setting or
country, and the specific tool used [5–10]. Inappropriate pre-
scribing and use of PIM can be associated with adverse out-
comes such as adverse drug events [11–13], hospitalisation [6,
14] and death [15].
A recently published systematic review identified 46 tools
or criteria for assessing inappropriate prescribing [16]. A prior
systematic review identified 14 criteria specific for individuals
aged 65 and older [1]. Generally, the assessment tools have
been developed based on expert opinion due to the lack of
high-quality studies on the use of drugs in older people [17],
although some tools have additionally used a literature search
[18, 19]. Criteria have been classified into explicit or implicit
or mixed approach [1]. Explicit criteria are generally lists of
medications or criteria which can be applied with little or no
clinical judgement but do not address individual differences
between patients [2]. Implicit criteria are based on the judge-
ment of a professional and are person-specific [20], requiring
individual patient data for application, however, they are time-
consuming and more dependent on the user [2]. No single
ideal tool has been identified so far, but each tool seems to
have its strengths and weaknesses, and the choice of a tool
may depend on the purpose of use (i.e. daily practice, re-
search) and availability of data [16].
Assessment tools are being used increasingly for the eval-
uation of prescribing quality in older people, but their appli-
cation cannot substitute the individual assessment of prescrib-
ing appropriateness [16]. One of the limitations of the tools is
the fact that the majority was developed following country-
specific guidelines, national drug markets and prescribing
habits, hence, limiting their transferability to other countries
[1, 21]. For instance, the German PRISCUS list of potentially
inappropriate medications, a purely explicit list, defines 83
PIM drugs, of which twelve are not on the drug market in
France, the USA and Canada. However, there are 124 drugs
on the PIM lists of these countries which are not part of the
German PRISCUS list, because seventy of them are not on the
German drug market and many others are almost never used
[22]. To the best of our knowledge, no assessment tool covers
the drug markets of several European countries and could thus
enable the analysis of European databases.
The present study was conceived when planning to
analyse the prescription of PIM among a European cohort
of older people with dementia participating in the
RightTimePlaceCare study [23]. The primary aim of our
study was to develop an expert-consensus list of potentially
inappropriate medications covering the drug markets of seven
European countries, which can be used for the analysis of
potentially inappropriate prescription patterns in and across
several European countries. Additionally, the list should be
applicable in clinical practice to alert health care professionals
to the likelihood of inappropriate prescribing, possible dose
adjustments required and therapeutic alternatives.
Methods
A research team consisting of a clinical pharmacologist, a
pharmacist, a nursing scientist and a geriatrician planned and
coordinated the development of the European Union (EU)(7)-
PIM list. Two members of the research team were developers
of the German PRISCUS list [22]. The study comprised five
consecutive phases:
1. Preparation of a preliminary PIM list. We prepared a
preliminary PIM list which contained 85 PIM (82 active
substances plus one combination of active substances and
two different preparations of one substance) from the Ger-
man PRISCUS list [22] and 99 PIM from the French [3],
American [24, 25] and Canadian [26] lists. These tools
have been used in research to evaluate the prescription of
PIM and factors associated with PIM use [5, 6, 14,
27–29]. The main reason for each drug being PIM was
formulated using the information provided by the original
lists. This process was supported by a comprehensive lit-
erature search. The anatomical therapeutic chemical
(ATC) code classification system was used (2011) [30].
2. Recruitment of experts on geriatric prescribing/
pharmacotherapy. We established a collaboration with
t h e S even t h F r amewo r k Eu r op e a n p r o j e c t
RightTimePlaceCare [23], a project aiming to develop
best practice recommendations for dementia care through-
out Europe. The consortium partners of this project sup-
ported the recruitment of experts on geriatric prescribing
or pharmacotherapy in their respective countries. Thirty-
three experts from six European countries agreed to par-
ticipate; they came from Finland (n=3), Estonia (n=9),
the Netherlands (n=4), France (n=2), Spain (n=7) and
Sweden (n=8). The following professions were represent-
ed as follows: geriatricians (n=14), pharmacists (n=3),
clinical pharmacologists (n=7) and other medical special-
ists (n=9). Experts were sent information documents de-
scribing the aims, concepts and steps of the study and
were asked whether they preferred to participate in the
expansion phase (phase 3), in the Delphi survey (phase
4), or in both.
3. Expansion of the preliminary PIM list. We asked thirteen
experts representing the six countries to expand the pre-
liminary PIM list by adding drugs that they considered
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should be PIM and which were not represented, paying
special attention to those drugs available on their respec-
tive countries’ markets. Expansion of the preliminary list
was Internet-based and concluded in May 2012.
4. Two-round Delphi survey. A two-round Delphi survey
was performed [31]. The first Delphi round took place
between October and December 2012, and the second
Delphi round between March and May 2013. In the first
round, we asked 29 experts to assess each drug of the
preliminary expanded list for appropriateness by using a
1–5 points Likert scale where B1^ represented BI strongly
agree that the drug is potentially inappropriate for older
people^; B2^, BI agree that the drug is potentially inappro-
priate for older people^; B3^, Baverage/neutral/
undecided^; B4^, BI disagree that the drug is potentially
inappropriate for older people^; B5^, BI strongly disagree
that the drug is potentially inappropriate for older
people^; and B0^, Bno answer; I do not feel qualified to
answer .^ Experts were asked to provide suggestions for
dose adjustments and safer therapeutic alternatives for
those drugs judged as inappropriate. Experts were free
to insert additional comments and were invited to expand
the list with any further drugs they considered to be PIM.
In the second Delphi round, we asked 28 experts to
assess the appropriateness of those drugs classified as
questionable PIM during the first round (see BExpert
agreement and statistics^), as well as the further sugges-
tions for PIM made by the experts during the first Delphi
round, and also eight drugs appearing in the recently pub-
lished updated Beers list [18]. Some PIM concepts were
adapted taking the experts’ suggestions made during the
first Delphi round into account. The additional sugges-
tions for PIM were given a justification as to why they
may be classified as PIM, taking published data into con-
sideration when necessary. Again, experts assessed the
appropriateness of these drugs and were asked to provide
dose adjustments, therapeutic alternatives, and to insert
additional comments if necessary. Drugs were classified
into PIM, non-PIM and questionable PIM (see BExpert
agreement and statistics^).
5. Preparation of the final PIM list. Dose adjustments and
drug alternatives suggested by the experts during the Del-
phi survey were compiled and included in the EU(7)-PIM
list, prioritising in each case those made by the higher
number of experts. Suggestions were complemented, if
necessary, with information available from the other
PIM lists and from Micromedex® [32], a commercially
available database which contains comprehensive infor-
mation on drug use. We identified those drugs for which
some discussion issues raised by the experts still remained
open and those drugs where inconsistency in the results
was identified after checking the literature. In order to
solve these problems, a reduced number of experts (n=
12) was invited to participate in the last brief survey which
took place in September 2013.
Expert agreement and statistics
Several approaches have been suggested in the literature to
define expert agreement within Delphi surveys [31]. In this
study, after the first and second Delphi rounds, we calculated
the means, the corresponding 95 % confidence intervals (CI)
and the medians of all Likert scores given to each drug; expert
agreement was considered if the CI of the mean score for each
drug did not cross over the value 3. Thus, each drug was
classified into PIM (if both the mean value of the score and
the upper limit of the CI were lower than 3), non-PIM (if both
the mean value of the score and the lower limit of the CI
exceeded 3) and questionable PIM (if the CI was on both sides
of the value 3). Statistical calculations were performed with
SPSS, version 21.0.
Results
The preliminary PIM list contained 184 drugs (including
two combinations of two drugs) and preparations (e.g.
sustained-release preparations of oxybutynine). Eight of the
13 invited experts (62 %) participated in the expansion
phase and suggested 75 additional drugs and preparations.
Twenty-six out of the 29 invited experts (90 %) participated
in the first Delphi round, and 24 out of the 28 invited ex-
perts (86 %) participated in the second Delphi round. Two
experts from Spain and three experts from Finland chose to
collaborate together in two teams to provide their assess-
ments in both Delphi rounds. All the 12 experts invited
participated in the last brief survey.
Figure 1 shows the development process of the list. In the
first Delphi round, experts assessed 259 drugs and prepara-
tions, of which the majority (n=234) were classified as PIM
and only one drug as non-PIM. In the second Delphi round,
experts assessed 79 drugs and preparations, comprising 23
questionable PIM, 47 further suggestions by experts, eight
additional drugs from the updated Beers list [18] and one drug
(naproxen) judged as PIM for which the main reason for PIM
was adapted taking recent published data and experts’ com-
ments into consideration. Again, 31 drugs and preparations
remained as questionable PIM and 46 drugs were classified
as PIM. Overall, after the third brief survey, 282 drugs and
preparations were classified as PIM, 29 as questionable PIM
and three as non-PIM.
The level of agreement between experts varied in the as-
sessment of appropriateness. For example, experts reached
consensus for diazepam being PIM with a mean Likert score
of 1.61, confidence interval between 1.32 and 1.89, and
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median of 2. Consensus was reached also for digoxin being
PIM (mean Likert score 2.19; confidence interval 1.57–2.81;
median 2), but in this case, the Likert scores ranged from 1 to
5. No consensus was reached on the appropriateness of some
drugs such as metamizole, which was classified as question-
able PIM. For this drug, the disparity seemed to be in part due
to the experts’ country of origin, since the majority of the
Spanish experts considered metamizole to be appropriate
when used in adequate doses, whereas the majority of Finnish
experts considered this drug to be clearly inappropriate.
The last brief survey consisted of 11 questions with
multiple-choice answers and covered issues regarding 13
drugs. The questions covered mostly dose-related issues
commented by the experts during the survey which remained
open (four drugs) and inconsistencies in the results identified
after checking the literature (three drugs). Additionally, the
research group asked the experts to provide their opinion on
the use of three drugs. Finally, the research group did minimal
corrections in the PIM which needed experts’ approval (three
drugs). All of the issues could be solved.
Table 1 displays an abbreviated version of the EU(7)-PIM
list, with the 72 PIM most frequently identified among the
participants of the RightTimePlaceCare survey [23], a Euro-
pean cohort of older people with dementia (data not shown).
Appendix 1 shows the complete EU(7)-PIM list, which
comprises 275 chemical substances (i.e. 7-digit ATC codes;
e.g. amitriptyline) including two combinations of two chemi-
cal substances, plus seven drug classes (i.e. 5-digit ATC
codes; e.g. triptans), belonging to 55 therapeutic classes (i.e.
4-digit ATC codes; e.g. antidepressants) and 34 therapeutic
groups (i.e. 3-digit ATC codes; e.g. the nervous system). Some
PIM concepts are dose-related (e.g. zopiclone used at doses
higher than 3.75 mg/day) or defined by length of use (e.g.
proton-pump inhibitors used longer than 8 weeks) or drug
regimen (e.g. insulin, sliding scale). Appendix 1 contains also
information on the number of experts who assessed each PIM,











+ 47 further suggestions by experts 
+ 8 additional drugs from the updated 
Beers list [18]
+ 1 drug judged as PIM for which the 
main reason for PIM was adapted with 
experts‘ comments and literature.
Preliminary PIM-List       
(184 drugs)
Expansion by experts         
(75 drugs)




Non-PIM               
(2 drugs)















aThis number comprises two groups of 2 and 3 experts, respectively, doing joint assessments.
Fig. 1 The development process
of the EU(7)-PIM list
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the mean, median and standard deviation of the scores given
by experts to each drug (Likert scale), and the results of the
compilation and selection of suggestions for dose adjustments
and therapeutic alternatives. Furthermore, Appendix 1 shows
two categories of those drugs (active substances characterised
by their ATC code) on the EU-PIM list that are included also
on other PIM lists. Category Ameans that precisely this active
substance is named as a PIMwhich should be avoided in older
people. Category B means that (i) this active substance is
characterised as a PIM only in the case of certain clinical
conditions or co-morbidities or (ii) this active substance is
not specifically named but considered as a PIM drug class
(e.g. anticholinergics or long-acting benzodiazepines). This
information refers to six international PIM lists or criteria [3,
18, 19, 22, 26, 33] and shows that 24 drugs do not appear as
PIM in any of the other lists, while the rest varies from
appearing in one list only to appearing in all the lists.
The full lists of questionable PIM and non-PIM and the
results of their assessments are presented in Appendix 2 and
3, respectively.
Discussion
We developed the EU(7)-PIM list in order to analyse the pre-
scription patterns of potentially inappropriate medication
(PIM) across several European countries, and more specifical-
ly among the people with dementia participating in the
RightTimePlaceCare Seventh Framework European project
[23]. We also aimed to develop a list that would be applicable
in clinical practice. The development of the EU(7)-PIM list
took several international PIM lists (i.e. the German PRISCUS
list [22], the American Beers list [18, 24, 25], the Canadian list
[26], and the French list [3]) into consideration, as well as
further drugs suggested by experts on geriatric prescribing
from seven European countries who belonged to different
professions.
The EU(7)-PIM list can be seen as a screening tool for
the identification of PIM for older people across many Eu-
ropean countries. We have covered several regions of Eu-
rope including Finland and Sweden in Scandinavia, France
and Spain in southern Europe, Germany and the Netherlands
in central Europe, and Estonia in eastern Europe. As shown
by Fialová et al. [5], the prevalence of PIM use in several
European countries varies widely, depending on the PIM
criteria set. Thus, the creation of a PIM list suitable for
pharmacoepidemiological studies and clinical use in Europe
seems to be mandatory. Attempts are being undertaken to
develop prescribing quality indicators which are useful for
the electronic monitoring of the quality of prescribing in
older people in Europe [34], and the EU(7)-PIM list could
represent a part of this.
We expect the EU(7)-PIM list to be a sensitive tool because
of its inclusive development process. In contrast, other tools
have been seen to be less sensitive, motivating some authors
to use two or three assessment tools for the assessment of PIM
use in their populations in order to increase the sensitivity [5,
6, 35, 36].
We aimed at developing a list which can be used even if the
clinical information available is minimal. Therefore, we chose
to develop explicit PIM criteria, restricted to drugs or drug
classes, in some instances restricted to high doses or
prolonged treatment duration. Thus, the EU(7)-PIM list is
suitable for pharmacoepidemiological applications using ad-
ministrative databases or surveys without any clinical infor-
mation about the individuals concerned.
To the best of our knowledge, this is the first list focusing
on chemical substances and requiring only a small amount of
clinical data for its application that has been developed taking
into account several existing PIM lists and European markets,
and that has been consented by experts from different Euro-
pean countries. This is also one of the few lists including
suggestions for dose adjustments and therapeutic alternatives.
Furthermore, the list enables a distinction between different
drugs belonging to the same pharmacological subgroup and
provides different suggestions for each of them. The recently
published screening tool of older person’s prescriptions
(STOPP)/screening tool to alert doctors to right treatment
(START) criteria for potentially inappropriate prescribing for
older people (version 2) were developed also with the partic-
ipation of a European panel of experts [19]. However, these
criteria often consider as PIM the use of pharmacological sub-
groups (e.g. thiazide diuretics) within specific clinical contexts
(e.g. history of gout, or current significant hypokalaemia).
Thus, the application of the START/STOPP criteria (both ver-
sions 1 and 2) [4, 19] requires clinical information, making
these criteria more suitable in the clinical context for a com-
prehensive drug review of individual patients.
The development process of the EU(7)-PIM list resembles
those of most other PIM lists, such as the French list [3], the
German PRISCUS list [22], the Austrian PIM list [37], but
also the most recent Beers list [18]. One major aspect of crit-
icism of all PIM lists is that the classification of PIM is usually
done without using evidence derived from randomised, con-
trolled trials and relies on the expertise of the participants in
the Delphi process [38]. However, this is partially justified by
the lack of evidence on drug efficacy and safety in older peo-
ple, due to their low enrolment in clinical trials [17]. In our
study, we identified relevant literature and used it during the
development process, but we did not systematically review
and report it, which may be seen as a limitation.
The Delphi technique has also been criticised because of
the lack of one standardised method, the difficulties in
analysing the data, the difficulties in defining what an expert
is, the often heterogeneous expert group, and the vague
872 Eur J Clin Pharmacol (2015) 71:861–875
concept of consensus [38]. In order to minimise the limitations
of the Delphi technique, in the present study, the characteris-
tics of the survey were predefined (e.g. steps, consensus con-
cept), and researchers provided experts with all necessary in-
formation to favour their engagement and participation. Re-
searchers compiled discussion issues raised by the experts and
took them into consideration for the consecutive steps of the
development process.
Only seven European countries participated in the devel-
opment of the EU(7)-PIM list (Estonia, Finland, France, Ger-
many, the Netherlands, Spain and Sweden). Furthermore, the
number of experts participating from some countries was lim-
ited. Certain drugs may not have been assessed for appropri-
ateness because they were neither included in the preliminary
list nor were they suggested by the experts. Certain drugs were
classified as PIM with a lower level of expert agreement than
others; some disagreements seemed related to the experts’
country of origin, which may show that there are international
differences in prescription patterns or attitudes. Regular up-
dates of the list should take into consideration the inclusion of
other European markets, the changes in the drug markets, the
prescribing tendencies, and above all, the new existing
evidence.
The application of the EU(7)-PIM list cannot substitute
the individual assessment of prescribing appropriateness,
which should take into account other aspects such as the
aims of the treatment, individual responses, and the older
person’s functional level, values and preferences, among
others [39]. This limitation has been recognised in the liter-
ature with regard to most tools assessing appropriateness of
prescription [16]. Despite its limitations, the concept of PIM
suggests that their use should be associated with less
favourable outcomes. Indeed, the use of PIM has been found
associated with a higher rate of adverse drug reactions in
several studies, as reported in a systematic review [40], with
some variations depending on the settings studied. Other
authors have suggested an association between PIM use
and other adverse outcomes such as injuries [41] and
hospitalisation [6, 14]. A limited number of studies on inter-
ventions involving the use of some of these tools have sug-
gested benefits in terms or relevant outcomes [42–44]. How-
ever, according to a recent systematic review, it is unclear
whether such interventions result in clinically significant im-
provements, although benefits in terms of reducing inappro-
priate prescribing may exist [45].
Future research should study whether the use of PIM ac-
cording to the EU(7)-PIM list shows any association with
clinically relevant outcomes for older people, and whether
the application of the list is associated with any benefits, both
in a population and on individual levels. The acceptability of
the list among health professionals should also be investigat-
ed, including the usefulness of the suggestions for drug ad-
justments and therapeutic alternatives.
In conclusion, the EU(7)-PIM list is an expert-consensus
list of potentially inappropriate medications for older people,
which was developed taking into consideration the medica-
tions appearing in six country-specific PIM lists, as well as
medications used in seven European countries. It is an explicit
list of chemical substances and contains suggestions for dose
adjustments and therapeutic alternatives. It can be applied as a
screening tool to identify potentially inappropriate medica-
tions in databases where little clinical information is available
and in individual data. It can also be used for international
comparisons of the prescription patterns of PIMs and may
be used as a guide in the clinical practice. The application of
the EU(7)-PIM list is a first step towards the identification of
areas of improvement in both individual and population levels
and towards the harmonisation of the prescription quality
throughout Europe.
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